Morepen’s Money Moves: Pharma Giant Posts Robust ₹3.85 Billion Revenue, Profit Surprises

Image Source: Medical Buyer

Morepen Laboratories has announced its financial results for the March 2025 quarter, reporting a total income of ₹3.85 billion (₹385 crore) and a net profit of ₹119.1 million (₹11.91 crore). The company continues to demonstrate resilience in revenue generation, with the latest quarter reflecting a stable performance in the face of industry headwinds.

Key Highlights:

Total income for the March quarter stood at ₹3.85 billion, maintaining consistency with previous quarters and underscoring the company’s robust operational base.
Net profit for the quarter was ₹119.1 million, indicating a decline compared to previous periods, primarily due to increased expenditure and margin pressures.
Sequential analysis shows that while revenue growth remains steady, profitability has faced challenges, as evidenced by a dip in both profit before tax and earnings per share.
The company’s focus on expanding its product portfolio and strengthening its presence in both domestic and international markets continues to drive topline growth.
Morepen Laboratories remains a significant player in the pharmaceutical and wellness sector, with ongoing efforts to innovate and diversify its offerings.

Despite the softness in net profit, Morepen Laboratories’ ability to sustain revenue growth highlights its resilience and adaptability in a competitive market. Investors and stakeholders will be closely watching the company’s strategic initiatives aimed at improving margins and driving future profitability.

Sources: Moneycontrol, BlinkX, Kotak Securities